$2.83 EPS Expected for Charles River Laboratories International, Inc. (NYSE:CRL) This Quarter

Brokerages expect that Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) will post earnings per share of $2.83 for the current quarter, according to Zacks. Six analysts have made estimates for Charles River Laboratories International’s earnings, with estimates ranging from $2.80 to $2.89. Charles River Laboratories International posted earnings of $2.61 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 8.4%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Charles River Laboratories International will report full year earnings of $11.63 per share for the current year, with EPS estimates ranging from $11.46 to $11.75. For the next fiscal year, analysts expect that the company will post earnings of $13.41 per share, with EPS estimates ranging from $12.77 to $13.70. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRLGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.04. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The business had revenue of $913.93 million during the quarter, compared to analyst estimates of $908.64 million. During the same quarter in the prior year, the business posted $2.53 EPS. Charles River Laboratories International’s revenue for the quarter was up 10.8% compared to the same quarter last year.

A number of research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft cut their price objective on Charles River Laboratories International from $409.00 to $350.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Jefferies Financial Group lowered Charles River Laboratories International from a “buy” rating to a “hold” rating and cut their price objective for the company from $370.00 to $280.00 in a research report on Monday, April 25th. Stephens assumed coverage on Charles River Laboratories International in a research report on Wednesday, April 6th. They set an “overweight” rating and a $377.00 price objective for the company. Bank of America cut their price objective on Charles River Laboratories International from $445.00 to $400.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Finally, StockNews.com assumed coverage on Charles River Laboratories International in a research report on Thursday, March 31st. They set a “hold” rating for the company. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $387.88.

CRL stock traded up $9.10 during trading on Friday, reaching $235.81. The company’s stock had a trading volume of 470,228 shares, compared to its average volume of 683,400. Charles River Laboratories International has a 1 year low of $217.20 and a 1 year high of $460.21. The company has a quick ratio of 1.12, a current ratio of 1.34 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $11.98 billion, a P/E ratio of 28.72, a price-to-earnings-growth ratio of 1.37 and a beta of 1.27. The company’s fifty day moving average is $269.49 and its 200-day moving average is $322.65.

In other news, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $315.46, for a total transaction of $6,309,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Massaro sold 178 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $230.96, for a total transaction of $41,110.88. Following the sale, the director now directly owns 4,677 shares of the company’s stock, valued at approximately $1,080,199.92. The disclosure for this sale can be found here. In the last three months, insiders sold 39,153 shares of company stock valued at $11,832,257. 1.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. purchased a new position in Charles River Laboratories International during the fourth quarter valued at approximately $27,000. McDonald Partners LLC purchased a new position in Charles River Laboratories International during the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp increased its holdings in Charles River Laboratories International by 200.0% during the third quarter. Jones Financial Companies Lllp now owns 75 shares of the medical research company’s stock valued at $31,000 after buying an additional 50 shares during the period. Clearstead Advisors LLC purchased a new position in Charles River Laboratories International during the third quarter valued at approximately $32,000. Finally, MUFG Americas Holdings Corp purchased a new position in Charles River Laboratories International during the fourth quarter valued at approximately $30,000. 93.06% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.